<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

September 22, 2020

T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates

Review the latest advances in the recall antigen assay, to provide an optimized system for screening and characterizing immunomodulatory drug candidates, including recapitulating aspects of a suppressed tumor microenvironment (TME).

Read More

September 22, 2020

T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates

Review the latest advances in the recall antigen assay, to provide an optimized system for...

Read More

September 17, 2020

HUB Technology: The Only Tumor Organoid Platform Available for Oncology Drug Discovery

Explore why adult stem cell (ASC)-derived HUB technology provides the only tumor organoid...

Read More

September 15, 2020

Targeting Peroxisome Proliferator-Activated Receptors for NASH Therapy

Review the roles of peroxisome proliferator-activated receptor (PPAR) isotypes in managing...

Read More

September 10, 2020

Genome-Wide RNAseq and Array-Based NanoString Transcriptomic Technologies: Which To Use and When?

Compare the pros and cons of two widely used transcriptomic technologies - genome-wide RNAseq...

Read More

September 8, 2020

Targeting the Fibroblast Growth Factor Axis for NASH Therapy

Review the roles of members of the FGF19 subclass of fibroblast growth factor (FGF) hormones in...

Read More

Upcoming Events


September 24, 2020

WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research

9am/1pm ET


September 30, 2020

WEBINAR: Animal Model Selection, Study Design, and Current Trends in Preclinical Obesity Research

11:00am EDT


October 14, 2020

Virtual Lunch and Learn: Translational Preclinical Platforms for CAR-T Cell Therapy

12-1:00pm BST


October 15-16, 2020 | PDT (UTC-7)

Biomarkers Series US

Virtual


October 24-25, 2020

32nd EORTC-NCI-AACR Symposium

Virtual